Drug Description in Trials / DrugBank / KEGG DRUG /


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
12-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE----2件: 6, 162
2A single blood sample for HLA typing----3件: 35, 38, 162
3AC-203 1% Topical Ointment----1件: 162
4AKST4290----2件: 6, 162
5ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED----5件: 36, 38, 53, 96, 162
6Allogenic mesenchymal stem cell isolated from adipose tissue----3件: 38, 96, 162
7Apremilast1件: Apremilast1件: D08860 4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬7件: 46, 50, 56, 97, 107, 162, 271
8ARAVA1件: Leflunomide1件: D00749 1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬3件: 46, 53, 162
9Avdoralimab1件: Avdoralimab---1件: 162
10Avdoralimab (IPH5401)1件: Avdoralimab---1件: 162
11Azathioprine1件: Azathioprine1件: D00238 --21件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162
12Azathioprine or Mycophenolate mofetil3件: Azathioprine,
Mycophenolate mofetil,
Mycophenolic acid
3件: D00238 ,
D00752 ,
D05096
2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 162
13Baricitinib1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬
35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
14Baricitinib 2 MG [Olumiant]1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬
35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 162
15Benralizumab1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
16Bertilimumab----2件: 97, 162
17BIV009----2件: 61, 162
18Blood test----6件: 36, 51, 107, 113, 162, 299
19CC----13件: 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271
20CC-10004----5件: 46, 56, 97, 162, 271
21Cellcept® in autoimmune bullous dermatoses----2件: 35, 162
22Clobetasol1件: Clobetasol1件: D07715 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬4件: 39, 46, 51, 162
23Clobetasol 0.05% Topical Ointment1件: Clobetasol1件: D07715 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
24Clobetasol Propionate2件: Clobetasol,
Clobetasol propionate
2件: D01272 ,
D07715
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 46, 162
25Clobetasol propionate + Methotrexate3件: Clobetasol,
Clobetasol propionate,
Methotrexate
3件: D00142 ,
D01272 ,
D07715
3件: DHFR,
DHFR2,
NR3C1 💬
6件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate 💬1件: 162
26Clobetasol propionate alone2件: Clobetasol,
Clobetasol propionate
2件: D01272 ,
D07715
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
27Clobetasol Propionate cream treatment2件: Clobetasol,
Clobetasol propionate
2件: D01272 ,
D07715
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
28Cortancyl1件: Prednisone acetate1件: D08416 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 35, 41, 162
29CORTANCYL 20 mg1件: Prednisone acetate1件: D08416 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162
30Cultivated oral mucosal epithelial sheet transplantation----2件: 38, 162
31Cyclophosphamide1件: Cyclophosphamide2件: D00287 ,
D07760
--44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331
32Cyclophosphamide 50Mg Oral Tablet1件: Cyclophosphamide2件: D00287 ,
D07760
--1件: 162
33Cyclosporine1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬37件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302
34Dapsone1件: Dapsone1件: D00592 --5件: 35, 42, 60, 84, 162
35Data report----1件: 162
36Dermoval----2件: 35, 162
37Dexamethasone1件: Dexamethasone1件: D00292 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬22件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299
38Dexamethasone 0.5mg/5ml solution1件: Dexamethasone1件: D00292 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162
39Dexamethasone 0.5mg/5ml solution in Mucolox™1件: Dexamethasone1件: D00292 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162
40DF2156A----1件: 162
41Double Dose----2件: 38, 162
42Doxycycline1件: Doxycycline2件: D00307 ,
D07876
--17件: 13, 23, 28, 34, 46, 84, 85, 89, 96, 97, 158, 161, 162, 167, 227, 280, 299
43Dupilumab1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬5件: 51, 97, 98, 160, 162
44Dupixent1件: Dupilumab1件: D10354 1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162
45EFGARTIGIMOD ALFA1件: Efgartigimod alfa1件: D11876 1件: FCGRT 💬-6件: 11, 14, 35, 53, 63, 162
46Efgartigimod PH20 SC----5件: 11, 14, 35, 63, 162
47Fasenra1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
48Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318
49Halometasone1件: Halometasone1件: D07202 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
50Imatinib1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
51Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
52INTERLEUKIN-21件: Human interleukin-2---10件: 2, 35, 49, 50, 53, 55, 65, 96, 97, 162
53IPH5401----1件: 162
54Ixekizumab1件: Ixekizumab1件: D10071 1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬8件: 36, 37, 46, 107, 160, 162, 269, 271
55Ladarixin1件: Ladarixin---1件: 162
56Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP5件: Dapsone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisolone,
Triamcinolone
5件: D00385 ,
D00472 ,
D00592 ,
D00752 ,
D05096
3件: IMPDH1,
IMPDH2,
NR3C1 💬
5件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬1件: 162
57Leflunomide1件: Leflunomide1件: D00749 1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300
58MabThera1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271
59Mabthéra----2件: 35, 162
60Mathéra----2件: 35, 162
61MEDI-563----5件: 44, 45, 98, 162, 299
62Medrone----4件: 46, 51, 83, 162
63MEPOLIZUMAB1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162
64Mepolizumab (a-IL-5 antibody)1件: Mepolizumab1件: D04923 1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 162
65Methotrexate1件: Methotrexate1件: D00142 2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
66Methylprednisolone1件: Methylprednisolone1件: D00407 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
67Minocycline1件: Minocycline1件: D05045 --13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299
68MMF----16件: 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 107, 162, 222, 224, 226, 299
69Mometasone1件: Mometasone1件: D08227 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
70MOMETASONE FUROATE1件: Mometasone1件: D08227 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162
71MTX----14件: 13, 35, 40, 46, 49, 50, 51, 60, 84, 96, 97, 107, 162, 271
72Mycophenolate1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
73Mycophenolate mofetil2件: Mycophenolate mofetil,
Mycophenolic acid
2件: D00752 ,
D05096
2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
74Myfortic1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬5件: 49, 66, 162, 222, 228
75Myfortic 180 mg1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 162
76Myfortic 180 mg Filmtabletten1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 162
77Nicotinamide1件: Nicotinamide1件: D00036 --8件: 2, 6, 18, 49, 97, 107, 162, 191
78NNC0215-0384----2件: 46, 162
79NOMACOPAN1件: Nomacopan1件: D11473 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 162
80Nomacopan (rVA576)1件: Nomacopan1件: D11473 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 162
81NPB-01----3件: 13, 14, 162
82Olive1件: Olea europaea leaf---5件: 13, 35, 49, 53, 162
83Olive oil2件: Olea europaea leaf,
Olive oil
1件: D03311 --5件: 13, 35, 49, 53, 162
84OMALIZUMAB1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299
85Oral corticosteroids (OCS)----1件: 162
86Otezla1件: Apremilast1件: D08860 4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬3件: 56, 107, 162
87Ozonated olive oil2件: Olea europaea leaf,
Olive oil
1件: D03311 --2件: 35, 162
88PREDNISOLONE1件: Prednisolone1件: D00472 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬42件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300
89Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331
90QGE031----1件: 162
91Restasis----2件: 53, 162
92Riboflavin1件: Riboflavin1件: D00050 --7件: 38, 46, 96, 97, 162, 168, 265
93RITUXIMAB1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
94Rituximab 1g IV1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 162
95Rituximab combined with Omalizumab2件: Omalizumab,
Rituximab
2件: D02994 ,
D05251
2件: FCER1A,
MS4A1 💬
5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 162
96RVA576----3件: 62, 109, 162
97Simvastatin1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
98Simvastatin-ratiopharm1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 162
99Simvastatin-ratiopharm®1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 162
100Single Dose----2件: 38, 162
101Solu-Medrone----3件: 51, 83, 162
102Tildrakizumab1件: Tildrakizumab1件: D10400 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 162, 271
103Tildrakizumab Prefilled Syringe1件: Tildrakizumab1件: D10400 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 162
104Topical garamycin cream----2件: 35, 162
105Topical infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬3件: 38, 39, 162
106Treatment systemic therapy (prednisone)1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
107Treatment with systemic therapy (doxycycline)1件: Doxycycline2件: D00307 ,
D07876
--1件: 162
108Treatment with systemic therapy (methotrexate)1件: Methotrexate1件: D00142 2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 162
109Treatment with systemic therapy (prednisone)1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
110Treatment with topical superpotent corticosteroid therapy----1件: 162
111Triamcinolone1件: Triamcinolone1件: D00385 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬11件: 35, 46, 53, 56, 70, 90, 96, 107, 162, 226, 298
112Tripterygium1件: Tripterygium wilfordii whole---8件: 46, 66, 67, 96, 162, 222, 224, 271
113Ustekinumab1件: Ustekinumab1件: D09214 3件: IL12A,
IL12B,
IL23A 💬
28件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271